RT Journal Article
SR Electronic
T1 Upper gastrointestinal tract lymphoma with Natalizumab: Evidence of impaired immune surveillance?
JF Neurology: Clinical Practice
FD Lippincott Williams & Wilkins
SP 10.1212/CPJ.0000000000000985
DO 10.1212/CPJ.0000000000000985
A1 Gomes, Lauren
A1 Watson, Emily
A1 Smith, Matthew
A1 Morris, Edward
A1 Boggild, Mike
YR 2020
UL http://cp.neurology.org/content/early/2020/10/06/CPJ.0000000000000985.abstract
AB The humanised recombinant monoclonal antibody natalizumab (Tysabri), is a selective antagonist of the α4 subunit of the leukocyte adhesion molecule integrin, VLA-3. Blockade of VLA-3 leads to inhibition of immune cell transmigration into target organs, notably the intestinal lining and central nervous system.1,2 Natalizumab is approved to treat relapsing-remitting Multiple Sclerosis (RRMS) in the US and Europe, and Crohn’s Disease in the US. Following approval in 2004, natalizumab was withdrawn in 2005 due to 3 reported cases of progressive multifocal leukoencephalopathy (PML). In 2006, it re-entered the market with additional monitoring requirements.